Treatment patterns for new or persistent immune thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at how people with immune thrombocytopenia (ITP) are treated in real life. It aims to understand which treatments work best for patients who have had ITP for up to 12 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ITP (immune thrombocytopenia) for 12 months or less.
- Your platelet count was below 30,000 at the time of diagnosis.
- You are 6 years old or older.
- You have medical records that can be reviewed for this study.
- You may have received any ITP treatment (except emergency platelet transfusions) or no treatment at all.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have immune thrombocytopenia (ITP), a condition where the blood doesn't clot properly because of low platelets. By tracking patients over time, researchers hope to learn more about the disease and how it affects people.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.